Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,067 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,060
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 399
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Type 1 Diabetes132
- Rheumatoid Arthritis131
- Atopic Dermatitis122
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections105
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California498
- Maryland198
- Alabama178
- Florida151
- Arizona150
- Massachusetts118
- New York114
- Texas112
- Illinois84
- Colorado81
Recruiting studies6,067 total
- NCT05852717RecruitingPhase 2
Epcoritamab plus GDP chemotherapy for relapsed large B-cell lymphoma
This Phase 2 study tests epcoritamab combined with GDP chemotherapy to treat adults whose large B-cell lymphoma has come back or did not respond to prior treatment. It aims to improve how safely and effectively the disease can be controlled after standard chemotherapy.
Indianapolis, IndianaAges 18 years+ - NCT05865054Recruiting
MRI check in early suspected giant cell arteritis
This trial tests how well a special MRI (picture scan) can evaluate giant cell arteritis when it’s newly suspected and symptoms started recently. It may help doctors confirm the diagnosis and decide on treatment sooner by comparing MRI findings with standard testing like biopsy or ultrasound.
Rochester, MinnesotaAges 50 years+ - NCT05858645RecruitingPhase 4
Deucravacitinib to correct immune signals in psoriasis
This Phase 4 study tests whether deucravacitinib can improve psoriasis by correcting abnormal immune-cell signals seen in people with moderate-to-severe disease. It may help reduce symptoms and improve control of psoriasis, while researchers also track immune changes.
San Francisco, CaliforniaAges 18–75 - NCT05849038RecruitingPhase 2
Treating inflammation to improve depression in HIV
This Phase 2 study looks at whether lowering inflammation can help improve depression symptoms in adults living with HIV. You may be able to join if your HIV is well controlled and you are currently experiencing major depression (or a certain type of bipolar depression).
Atlanta, GeorgiaAges 18–65 - NCT05875155Recruiting
Saving eggs by freezing ovarian tissue during cancer or surgery care
This trial looks at freezing ovarian tissue to help protect future fertility for people who may lose ovarian function from medical treatments or ovarian surgery. It may help you preserve the chance to have children later when egg or embryo freezing alone isn’t an option.
Pittsburgh, PennsylvaniaAges Up to 39 years - NCT05857969RecruitingPhase 1
Testing cancer drug response on removed tumor tissue
This early study uses tumor tissue (or bone marrow from blood cancers) and performs lab tests to see which cancer drugs may work better for each person. It also collects genetic information from blood or a saliva swab to help understand why cancers respond differently.
Miami, FloridaAges 1 day–21 years - NCT05858619RecruitingPhase 4
Study of skin response to dupilumab in eczema
This trial studies how the body’s “molecular signals” change in the skin after using dupilumab for eczema. It may help researchers understand who benefits most from treatment.
San Francisco, CaliforniaAges 18 years+ - NCT05865301Recruiting
Outcomes after approved immunotherapy for young blood cancer patients
This study looks at the real-world results of treating certain B-cell blood cancers in children and young adults with commercially available immunotherapy. It may help doctors better understand how these treatments work for patients after relapse or when they need additional therapy.
Tucson, ArizonaAges Up to 26 years - NCT05847569RecruitingPhase 2
Testing alternating doses of belantamab for hard-to-treat myeloma
This Phase 2 trial tests whether alternating doses and schedules of belantamab mafodotin can help people with multiple myeloma that has returned or kept progressing after several prior treatments. You may be eligible if your disease has specific measurable signs and your blood counts and organs are healthy enough for study treatment.
Jacksonville, FloridaAges 18 years+ - NCT05866757Recruiting
Stopping maintenance treatment in multiple myeloma patients
This study looks at whether it is safe to stop “maintenance” treatment for people with multiple myeloma who have been in remission for a long time, including those who stopped early because of side effects. It tests whether stopping therapy affects disease control and helps reduce ongoing treatment burden.
Cork, IrelandAges 18 years+ - NCT05849753Recruiting
Access program for diabetes tech in kids with type 1
This trial helps children with type 1 diabetes get advanced diabetes technology, aiming to reduce gaps in access for families with fewer resources. It will check whether these tools are usable and helpful for diabetes care in children who meet the study needs.
Jacksonville, FloridaAges 6–17 - NCT05859191Recruiting
Study of immune cell markers in people with lupus
This study looks at how certain immune cells (natural killer T cells) behave in people with systemic lupus, by measuring specific immune receptor markers in blood. It may help researchers better understand lupus and how it can connect with other conditions like antiphospholipid syndrome or Sjögren’s.
ToursAges 18 years+ - NCT05858424Recruiting
Day hospital program to improve young cancer survivors’ well-being
This study tests a structured “end-of-treatment” day hospital program to improve quality of life for adolescents and young adults after cancer treatment. You may be offered follow-up and supportive care soon after finishing treatment to help you feel better physically and emotionally.
LyonAges 15–25 - NCT05876923Recruiting
Exercise study for immune changes in indolent blood cancers
This study looks at how an exercise program may change parts of the immune system in people with slow-growing (indolent) non-Hodgkin lymphoma or chronic lymphocytic leukemia (CLL/SLL). It may help researchers understand which immune changes could be important for your condition.
Scottsdale, ArizonaAges 18–80 - NCT05853965RecruitingPhase 1/Phase 2
Study of belantamab plus venetoclax for relapsed myeloma
This Phase 1/2 trial tests whether combining belantamab mafodotin with venetoclax can treat multiple myeloma that has come back or did not respond (relapsed/refractory). It focuses on a specific myeloma subtype with a t(11;14) genetic marker, aiming to reduce the cancer in people who have already had several treatments.
Hamburg, HamAges 18 years+ - NCT05848765RecruitingPhase 2
Trial for relapsed follicular lymphoma after prior chemo
This Phase 2 trial studies treatment options for follicular lymphoma that has returned or did not respond to prior therapy. It compares a standard chemotherapy approach against another study treatment to see which works better and is tolerable.
AberdeenAges 18 years+ - NCT05866523Recruiting
Help for people newly diagnosed with HIV
This study is for adults who were recently diagnosed with HIV and are not yet on HIV treatment (ART). It aims to test ways to support care and help people get connected with the right HIV specialists.
Loma Linda, CaliforniaAges 18 years+ - NCT05858034Recruiting
Study of aging and frailty in people with HIV over 50
This study looks at what makes some people with HIV become “pre-frail” or frail as they get older. It uses questionnaires and other checks to understand challenges to healthy aging and may help improve future support and care.
Winston-Salem, North CarolinaAges 50 years+ - NCT05858684RecruitingEarly Phase 1
CAR-T therapy for hard-to-control lupus
This early-phase study tests a special immune therapy (CAR-T cells) made to target disease-driving immune cells in adults with lupus that has not improved despite standard treatments. It may offer a new option for people with severe, active lupus symptoms.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05858632RecruitingPhase 4
Study immune patterns during guselkumab skin response in psoriasis
This trial studies how the immune system changes in the skin after guselkumab treatment for psoriasis, including the scalp. You may be asked to meet certain scalp severity and medication safety rules.
San Francisco, CaliforniaAges 18 years+ - NCT01266915Recruiting
Cutaneous lupus skin disease registry study
This study builds a registry (a protected medical record) of people with cutaneous lupus and/or systemic lupus that affects the skin. It gathers skin exam information and may include a skin biopsy and blood tests to better understand these conditions.
Dallas, TexasAges 18 years+ - NCT04785989Recruiting
Blood and marrow testing to study metabolism in CLL
This study measures how your body’s metabolism works in people with chronic lymphocytic leukemia (CLL). It uses blood tests, and for some people, a bone marrow sample, to better understand what’s happening and potentially guide future treatments.
Madison, WisconsinAges 18 years+ - NCT05813964RecruitingPhase 3
Event-driven HIV prevention pill for men who have sex with men
This trial tests a new way to take HIV prevention medicine (PrEP) only around the time you have sex, using a pill called TAF/FTC. It aims to see if this 'on-demand' method is effective, safe, and acceptable, and could offer a more flexible option than taking a pill every day.
ParisAges 18 years+ - NCT05819944Recruiting
LUNG-TECH trial testing new tools to diagnose asthma
This trial studies new technologies to help doctors diagnose asthma and better understand airway inflammation. It may help you (or healthy volunteers, if eligible) by allowing your breathing tests and inflammation markers to be measured with newer diagnostic tools.
Portsmouth, HampshireAges 17 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,067 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,241 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.